PHATPhathom Pharmaceuticals, Inc.

PHAT Stock Price, Valuation & Chart | Phathom Pharmaceuticals, Inc.

Compare

$8.800+0.14 (+1.62%)

At close · 25 Aug 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology PHAT intrinsic value Is PHAT overvalued or undervalued

Overview Financials Dividends Ratios

PHAT Historical price chart

PHAT Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization711.93M

PE Ratio-6.87

EPS-1.28

Trading Volume969.18K

Today's High/Low8.94/8.64

Dividend Yield0.00

52 Week High/Low18.31/8.21

Shares Outstanding80.90M

PHAT Financial Statement

PHAT Analyst ratings

PHAT Analysis & performance metrics

PHAT Company profile

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has…

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III…

PHAT Management team

Name

Position

Martin J. Gilligan

Chief Commercial Officer

David A. SocksCTO

Co-Founder & Director

Azmi Nabulsi M.D., M.P.H.COO

Co-Founder & Chief Operating Officer

Tom Harris

Chief Development Sciences Officer

Molly Henderson CPA, MBACFO

Chief Financial & Business Officer

Steven L. Basta M.B.A.CEO

Chief Executive Officer, President & Director

Jonathan Bentley

Senior Vice President & Head of Sales

Paul Cocja

Chief People Officer

Name

Position

Martin J. Gilligan

Chief Commercial Officer

David A. SocksCTO

Co-Founder & Director

Azmi Nabulsi M.D., M.P.H.COO

Co-Founder & Chief Operating Officer

Tom Harris

Chief Development Sciences Officer

Molly Henderson CPA, MBACFO

Chief Financial & Business Officer

Steven L. Basta M.B.A.CEO

Chief Executive Officer, President & Director

Jonathan Bentley

Senior Vice President & Head of Sales

Paul Cocja

Chief People Officer

Management Team

Martin J. Gilligan

Chief Commercial Officer

David A. SocksCTO

Co-Founder & Director

Azmi Nabulsi M.D., M.P.H.COO

Co-Founder & Chief Operating Officer

Tom Harris

Chief Development Sciences Officer

Molly Henderson CPA, MBACFO

Chief Financial & Business Officer

Steven L. Basta M.B.A.CEO

Chief Executive Officer, President & Director

Jonathan Bentley

Senior Vice President & Head of Sales

Paul Cocja

Chief People Officer

Management

Martin J. Gilligan

Chief Commercial Officer

David A. SocksCTO

Co-Founder & Director

Azmi Nabulsi M.D., M.P.H.COO

Co-Founder & Chief Operating Officer

Tom Harris

Chief Development Sciences Officer

Molly Henderson CPA, MBACFO

Chief Financial & Business Officer

Steven L. Basta M.B.A.CEO

Chief Executive Officer, President & Director

Jonathan Bentley

Senior Vice President & Head of Sales

Paul Cocja

Chief People Officer

Total 8 executives

PHAT Frequently asked questions

What is Phathom Pharmaceuticals, Inc. (PHAT) Stock Price?

Current stock price of Phathom Pharmaceuticals, Inc. (PHAT) stock is $8.800. The stock price is +1.62% higher in the session. The intraday range can be seen from this page. Volume of Phathom Pharmaceuticals, Inc. (PHAT) stock is 969.18K.

Last updated at 25 Aug 2026, 08:00 pm.

Why is the Phathom Pharmaceuticals, Inc. (PHAT) stock price going up or down today?

The stock price of Phathom Pharmaceuticals, Inc. (PHAT) can change with earnings, company news, and overall market sentiment. Phathom Pharmaceuticals, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Phathom Pharmaceuticals, Inc. stock expensive at its current price?

Whether Phathom Pharmaceuticals, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for PHAT on this page is -6.87. EPS on this page is -1.28. Compare those figures with peers and growth expectations before deciding if the current Phathom Pharmaceuticals, Inc. price is justified.

How has the stock price of Phathom Pharmaceuticals, Inc. (PHAT) performed historically?

Historical performance for Phathom Pharmaceuticals, Inc. (PHAT) is shown on the price chart on this page. Review multi-period moves alongside volume to see how PHAT reacted to past earnings and market events.

Should I buy Phathom Pharmaceuticals, Inc. (PHAT) stock, at this price?

Buying Phathom Pharmaceuticals, Inc. (PHAT) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.